Given the secondary analysis of RTOG 0617, should IMRT be considered standard of care in locally advanced non-small cell lung cancer?

The secondary analysis of RTOG 0617 (Chun et al. JCO.2016) supports the notion that IMRT should be the standard of care for the treatment of locally advanced non-small cell lung cancer (NSCLC). This study (0617) compared chemotherapy +either 60 Gy or 74 Gy of conventionally fractionated RT. The seco...

I think some caution is warranted here. The secondary analysis from 0617 does bring up very interesting findings regarding lower V20 and a NS 2yr survival increase with IMRT versus 3D.

The most significant point though is that the trial wasn't designed to compare 3D to IMRT. Results from secondary ...

The 0617 trial has delivered more puzzles than credible, reliable answers. A second secondary analysis has just appeared in JCO suggesting heart dose may also be associated. In addition to the design of high vs. low dose TRT, there was also +/- cetuximab step, and a stratification of IMRT vs 3-D. T...